Merck Life Science

Congratulations to Fuse Vectors for winning 2024 Merck Life Science European Advance Biotech Grant for its infinitely scalable gene therapy manufacturing platform! Cell and gene therapy has the potential to treat once-incurable diseases with a single therapy. Fuse Vectors novel gene therapy manufacturing platform helps accelerate production speeds while reducing costs and increasing access to life-saving treatments. With over three decades of experience supporting cell and gene therapy development, we are thrilled to work with Fuse Vectors to advance treatments for patients suffering from diseases previously thought to be incurable and untreatable.

Volunteers from our Molsheim and Darmstadt sites had an amazing time at Science Days at Europa Park! Over three days, more than 4,100 young minds explored tiny robots, fascinating microbes, and all kinds of fun science activities. Check out the highlights below! #SPARKCuriosity

Imagine a world where once-incurable diseases are now curable, where science is more sustainable from the beginning and where AI finds new drug targets in minutes, not years. I can. Because it’s already becoming reality.  Our new Merck Group vision – “Sparking discovery, elevating humanity” – perfectly captures this emerging reality and the bright future that lies ahead. We’ve made tremendous progress in tackling the biggest scientific challenges, and we’re only getting started. Since our beginnings in a small pharmacy in Darmstadt 356 years ago, Merck has embraced science and technology as a powerful force for good, delivering breakthroughs that enable brighter, healthier, and more sustainable lives for millions of people around the world. At Merck Life Science, this culture of collaboration and innovation endures today. Our 27,000 colleagues are united in driving progress that fulfills our purpose to impact life and health with science. #SparkingDiscoveryElevatingHumanity

What if we could make antibody-drug conjugates (ADCs) faster and safer? These powerful medicines target cancer cells while sparing healthy ones. Joe Cianciolo breaks down how the new Mobius ADC Reactor is revolutionizing ADC production by overcoming a major hurdle the industry previously faced.

Science is at the heart of everything we do. This #WorldScienceDay, we’re celebrating by hearing from a few of our talented scientists on what science means to them. Here’s to the curiosity, passion, and innovation that drive us to impact people around the world, every day.

Science is everywhere. It can be easy to forget the impact that it has on almost every part of our lives. From the medicines or treatments we rely on and the tools that helped create them, to the technology in our pockets and plants that feed us – it’s impossible to escape. As we celebrate #WorldScienceDay, we're reminded of the power of science – the impressive breakthroughs and the ordinary achievements. It’s a journey of iteration, collaboration, failure and setbacks. A journey built on the shoulders of scientists who paved the way before us. In short, science is all around us, and our 27,000 colleagues across Merck Life Science are here to support that scientific journey every step of way.

Congratulations to Duy-Viet Vo from the University of Illinois Chicago for winning the 5th Compound Challenge! The challenge asked participants to design the best synthetic route for a target molecule and Duy-Viet Vo did just that! Want to enter the winner's circle yourself? Sign-up for the 6th Compound Challenge now at http://ms.spr.ly/6040WVv7i

🎈 Ever wondered why helium makes balloons float? At the Curiosity Cube, our mobile science lab, employee volunteers like G help answer the curious questions left by our student visitors! #SPARKCuriosity Interested in learning more about the Curiosity Cube? Visit: http://ms.spr.ly/6049WRSOh

It's looking a little spooky in our bioprinting labs 🎃 👻. Rather than carving our pumpkins, we're printing them layer by layer. Interested in learning more about 3D bioprinting? Visit: http://ms.spr.ly/6047WuPjh

Exciting news! We’re investing €70 million to triple our Antibody-Drug Conjugate (ADC) manufacturing capacity in St. Louis, Missouri. This expansion reinforces our commitment to advancing these cutting-edge novel therapies, and to our clients and ultimately patients. ADCs precisely target cancer cells, sparing healthy ones—one of the most promising advances in cancer treatment today. Together with our clients, we’re unlocking ADCs’ full potential to impact life and health with science. Learn more here: http://ms.spr.ly/6045W3d5U